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Abstract
Fibroblasts derived from the lungs of patients with idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc)
produce low levels of prostaglandin (PG) E2, due to a limited capacity to up-regulate cyclooxygenase-2 (COX-2). This
deficiency contributes functionally to the fibroproliferative state, however the mechanisms responsible are
incompletely understood. In the present study, we examined whether the reduced level of COX-2 mRNA expression
observed in fibrotic lung fibroblasts is regulated epigenetically. The DNA methylation inhibitor, 5-aza-2′-deoxycytidine
(5AZA) restored COX-2 mRNA expression by fibrotic lung fibroblasts dose dependently. Functionally, this resulted in
normalization of fibroblast phenotype in terms of PGE2 production, collagen mRNA expression and sensitivity to
apoptosis. COX-2 methylation assessed by bisulfite sequencing and methylation microarrays was not different in
fibrotic fibroblasts compared with controls. However, further analysis of the methylation array data identified a
transcriptional regulator, chromosome 8 open reading frame 4 (thyroid cancer protein 1, TC-1) (c8orf4), which is
hypermethylated and down-regulated in fibrotic fibroblasts compared with controls. siRNA knockdown of
c8orf4 in control fibroblasts down-regulated COX-2 and PGE2 production generating a phenotype similar to that
observed in fibrotic lung fibroblasts. Chromatin immunoprecipitation demonstrated that c8orf4 regulates COX-2
expression in lung fibroblasts through binding of the proximal promoter. We conclude that the decreased capacity of
fibrotic lung fibroblasts to up-regulate COX-2 expression and COX-2-derived PGE2 synthesis is due to an indirect
epigenetic mechanism involving hypermethylation of the transcriptional regulator, c8orf4.
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INTRODUCTION
Pulmonary fibrosis is a progressive disease that has a poor pro-
gnosis and for which there is currently no adequate therapy. It can
occur in isolation, as in idiopathic pulmonary fibrosis (IPF) or
in association with multi-organ connective tissue diseases, such
as systemic sclerosis (SSc) [1,2]. In the most common and ag-
gressive form, IPF, mean survival time from diagnosis is only
2–3 years [3].
The pathogenesis of pulmonary fibrosis is incompletely un-
derstood, although it is considered to develop through aberrant
injury repair mechanisms with the fibroblast/myofibroblast a key
Abbreviations: 5AZA, 5-aza-2′ -deoxycytidine; c8orf4, chromosome 8 open reading frame 4 (thyroid cancer protein 1, TC-1); COX-2, cyclooxygenase-2 (PTGS2,
prostaglandin-endoperoxide synthase 2); DNMT, DNA methyltransferase; FasL, Fas ligand; IPF, idiopathic pulmonary fibrosis; PG, prostaglandin; PGE2, prostaglandin E2; SSc, systemic
sclerosis; TGF-β, transforming growth factor-β; TSA, trichostatin A.
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effector cell [4,5].Wehave previously reported that fibroblasts de-
rived from the lungs of patients with IPF and SSc exhibit reduced
capacity to up-regulate cyclooxygenase-2 (COX-2, PTGS2) and
its downstream anti-fibrotic product prostaglandin (PG) E2, com-
pared with control lung fibroblasts, and that this imparts a func-
tionally profibrotic phenotype to the cells [6]. In addition, the
inability to up-regulate COX-2 and PGE2 has been demonstrated
to contribute to reduced HGF production by IPF fibroblasts [7].
The fundamental importance of COX-2 and PGE2 as anti-fibrotic
mediators is supported by animal studies, demonstrating that ge-
netic COX-2 deficiency or COX inhibition enhances fibrotic re-
sponses in the lung [8–10]. Similarly, enhanced fibrotic responses
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inGranulocyte-macrophage colony stimulating factor (GM-CSF)
deficient mice are associated with diminished PGE2 production
[10,11]. Conversely, protection from fibrosis in animals deficient
in CCR2, 5-lipoxygenase or transgenic overexpression of TNFα
is at least partly attributable to up-regulation of PGE2 [12–15].
Together, these data demonstrate the critical importance of COX-
2 and PGE2 in preventing the development of pulmonary fibrosis
in animal models and human disease. However, the mechanisms
responsible for limited COX-2 expression in fibroblasts in the
lungs of patients with pulmonary fibrosis are incompletely un-
derstood.
Accumulating evidence suggests that altered epigeneticmarks
such as DNA hypermethylation and histone hypoacetylation con-
tribute to the silencing of anti-fibrotic genes in IPF lung and SSc
skin fibroblasts [16,17], the development of renal and radiation-
induced skin fibrosis [18,19] and fibroblast to myofibroblast dif-
ferentiation [20]. Furthermore, COX-2 promoter methylation and
histone deacetylation have been implicated in COX-2 gene silen-
cing in cancer [21]. Recent studies examining DNA methylation
in whole human lung tissue and cultured lung fibroblasts have
shown multiple differentially methylated genes in IPF [22–24].
However, there is little information on the role of altered DNA
methylation in the regulation of COX-2 in IPF and SSc lung
fibroblasts.
We hypothesized that DNA hypermethylation may contribute
directly or indirectly to silencing of COX-2 expression in fibrotic
lung fibroblasts.We show that treatmentwith aDNAmethyltrans-
ferase (DNMT) inhibitor increased COX-2 expression of fibrotic
lung fibroblasts towards control levels, restored responsiveness
to COX-2/PGE2 inducing agents and normalized fibroblast func-
tion. Although COX-2 was found not to be directly methylated,
we identified a COX-2 binding transcriptional regulator, chromo-
some 8 open reading frame 4 (thyroid cancer protein 1, TC-1)
(c8orf4), that is hypermethylated and down-regulated in fibrotic
lung fibroblasts; knockdown of which in control fibroblasts in-




Fibrotic lung tissue was obtained from either transplant surgery
or lung biopsies and control tissue from histologically normal
areas of peripheral lung removed at lung cancer resection, as
previously described [25]. Primary fibroblast cultures were es-
tablished as previously described [6] and used before passage 8.
Patient details: Control, n = 7, aged 56+− 6 years, 2 male; IPF,
n= 10, aged 64+− 3 years, 5 male; SSc, n= 8, aged 52+− 1 years,
1 male). All tissue was obtained with appropriate consent and its
use approved by the relevant research ethics committee.
Cellswere routinely plated in 6-well plates inDulbecco’smod-
ified Eagle’s medium (DMEM) supplemented with 10% (v/v)
FCS, 100 unit/ml penicillin and 100 mg/ml streptomycin (Invit-
rogen) and cultured at 37 ◦C in a humidified atmosphere of air
containing 10% CO2. Once confluent, the medium was removed
and replaced with 0.4% FCS containing medium without antibi-
otics, and incubated for 24 h. Medium containing transforming
growth factor-β1 (TGF-β1) (1 ng/ml final concentration) was ad-
ded and incubated for up to 24 h before harvesting. For mRNA
processing studies, following 3 h incubation with TGF-β1, actin-
omycin D, a transcription inhibitor, was added at a final concen-
tration of 3 μg/ml to the existing medium, and cells harvested
0–75 min later for RNA extraction.
For the epigenetic studies, cells were seeded in 6-well plates
at less than 30% confluence 24 h before treatment. 5-Aza-2′-
deoxycytidine (5AZA), a DNMT inhibitor (Sigma–Aldrich), was
added at the indicated concentrations to the culture medium and
replaced at 24 h intervals for 3 days. Cells were then placed in
0.4% FCS medium containing 5AZA at the same concentration
with or without trichostatin A (TSA), an inhibitor of histone
deacetylases, at a concentration of 300 nM (Sigma–Aldrich) for
a further 24 h as described previously [21]. Cells were then har-
vested for total RNA or DNA extraction.
For microarray analysis and bisulfite sequencing experiments,
500,000 cells were seeded in a T175 flasks, 24 h before treatment
with or without a daily dose of 1 μM 5AZA until cells were con-
fluent (1 week, to ensure aminimumof 3 population doublings).
DNA was extracted (Nucleon, SL8501) and bisulfite converted
as described below.
qPCR
RNA was isolated using TRI-Reagent (Sigma–Aldrich) and
DNase treated with DNA-free (Ambion). cDNA was synthes-
ized using qScript (Quanta Biosciences). qPCR was performed
using MESA GREEN qPCR MasterMix Plus for SYBR® Assay
(Eurogentec) on an Eppendorf Realplex4 Mastercycler. Cycling
conditions were as follows: 95 ◦C for 5 min; and 40 cycles of
95 ◦C (10 s) and 62 ◦C (45 s). Data were normalized to either 18S
or a combination of HPRT , YWHAZ and EIF4A2 (as determined
by geNorm). Primers detailed in Supplementary Table S1.
PGE2 quantification
PGE2 was measured using a Biotrak Enzyme-immunoassay (GE
Healthcare) according to the manufacturer’s instructions.
Induction and detection of apoptosis
Fas ligand (FasL)-induced apoptosis was measured in fibroblasts
treated with or without 5AZA, as previously described [25].
DNA methylation analysis
DNA extracted from fibroblasts treated with or without 5AZA
was bisulfite converted using EZ DNA Methylation-Gold
TM
(Zymo Research). Bisulfite converted DNA was analysed us-
ing Illumina Infinium Human Methylation 450 array, bisulfite
sequencing or pyrosequencing.
Bisulfite sequencing
The DNA samples were bisulfite converted using an EZ DNA
Methylation-Gold
TM
Kit (Zymo Research). PCR was performed
on a tetrad PTC-225, Peltier Thermal cycler. PCR cycling con-
ditions were: 94 ◦C for 5 min, followed by 10 cycles of 94 ◦C
for 20 s, touchdown from 60 ◦C to 50 ◦C (−1◦/cycle) for 20 s
and 72 ◦C for 30 s, followed by a further 35 cycles at 50 ◦C
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annealing temperature. PCR products were resolved on a 1%
agarose gel and PCR products purified using a QIAquick gel ex-
traction kit (Qiagen, Germany) prior to DNA sequencing (WIBR,
UCL). The relative methylation at each CpG site was determined
by area under the curve analysis using ImageJ software, as previ-
ously described [26]. Primer details are provided in Supplement-
ary Table S1.
Pyrosequencing
Cells were seeded in T75 culture flasks and treated as described
above with 10 μM 5AZA. DNA was extracted and bisulfite con-
verted, as described above. Pyrosequencing assays were designed
using the PyroQ assay design software. A common tagwas placed
on either the forward or reverse primer (depending on the strand
to be sequenced) and a common universal biotinylated primer
was used for all reactions as previously described [27]. PCR was
performed using a nested PCR for specific amplification and cyc-
ling conditions included denaturation at 95 ◦C for 4 min, followed
by 10 cycles of 94 ◦C for 15 s, touchdown from 60 ◦C to 50 ◦C
(−1◦/cycle) for 15 s and 72 ◦C for 20 s, followed by a further
30 cycles at 50 ◦C annealing temperature. The second PCR used
2 μl of a 1:10 dilution of the first PCR as template and the same
cycling conditions. All products were confirmed to be single
bands by agarose gel electrophoresis. Methylation values were
calculated as an average of all 10 CpG sites within each assay
as determined by the Pyro Q-CpG Software (Biotage). Primers
detailed in Supplementary Table S2.
Immunohistochemistry
Immunohistochemical staining was performed on formalin-
fixed, paraffin-embedded sections of human lung tissue using
the avidin–biotin antibody complexing method, as previously
described [28]. c8orf4 and rabbit IgG antibodies used were
ab121923 and ab27478 (Abcam).
siRNA knockdown
Cells were seeded and transfected using INTERFERin (Polyplus
Transfection), following the manufacturer’s instructions. c8orf4
siRNAor negative control siRNA (#4392420 and #4390846, Am-
bion) were used at 10 nM. RNA and protein were isolated for
qPCR and Western blot analysis.
Western blotting
Twenty micrograms of protein was resolved on a 12.5% polyac-
rylamide gel, transferred on to a PVDF membrane and immuno-
blotted for COX-2 and β-actin. Antibodies used: ab52237,
Abcam; A5441, Sigma–Aldrich; P0448 and P0260, Dako,
Glostrup.
ChIP
ChIP was performed as previously described [29]. Briefly, cells
were fixed in 1% formaldehyde for 15 min at room temper-
ature and then quenched with 0.125 M glycine for 5 min. To
generate DNA fragments of 0.2–1 kb, 1× 106 cells were son-
icated by Bioruptor
TM
(Diagenode) on maximum power for
8 min with an on–off interval of 30 s. Samples were pre-cleared
with Protein A agarose/Salmon Sperm DNA 50% Slurry (16–
157, Millipore), before being immunoprecipitated with 3.5 μg
of c8orf4 antibody (ab133885, Abcam) overnight at 4 ◦C. For
negative/isotype control rabbit IgG was used (ab27478, Ab-
cam). Agarose/antibody/histone complexes were collected and
washed before elution of protein/DNA complexes. Cross-linking
of products was reversed by heating overnight at 65 ◦C and then
treated with proteinase K at 45 ◦C for 1 h. DNA was recovered
by QIAquick purification kit (Qiagen). DNA was amplified by
PCR using a panel of COX-2 promoter primer sets (Supplement-
ary Table S1). PCR cycling conditions were: 94 ◦C for 5 min;
followed by 40 cycles of 94 ◦C (1 min), 58 ◦C (1 min) and 72 ◦C
(1 min); and 72 ◦C for 5 min. PCR products were visualized on a
1.5% agarose gel.
Statistical analysis
Statistical analysis was performed usingGraphpad Prism (Graph-
PadSoftware).Datawere evaluated using either one-wayANOVA
with Tukey’s post hoc pair wise comparisons or two-way ANOVA
with a Bonferroni post-test. For microarray data, an adjusted P
value of<0.05 and aβ value0.136was considered significant
[30].
RESULTS
IPF- and SSc-derived fibroblasts exhibit a limited
capacity for COX-2 mRNA transcription
Consistent with previous results [6,31], fibroblasts from IPF and
SSc groups produced three- to five-fold lower basal levels of ma-
ture COX-2mRNA compared with controls (Figure 1A). Similar
differences between groups were observed in TGF-β1-induced
levels of COX-2mRNA (Figure 1B). COX-2mRNA levels in the
control group increased approximately six-fold in response to
3 h stimulation with TGF-β1 (P< 0.001). COX-2 mRNA levels
also increased in response to TGF-β1 in both the fibrotic groups;
however, induced levels were still approximately three-fold lower
than in controls (P< 0.001). Additional studies comparing levels
of the mature and nascent COX-2 transcript revealed an almost
identical time-dependent response to TGF-β1, with significantly
lower levels of both nascent and processed transcripts seen in
the fibrotic fibroblasts compared with control (Supplementary
Figures S1A and S1B). Further, no differences were observed at
the level of mRNA stability, when actinomycin D chase exper-
iments were performed (Supplementary Figure S1C), thus sug-
gesting that the differences in mRNA expression between control
and fibrotic lung fibroblasts result from deficiencies in COX-2
transcription.
DNA demethylation but not histone acetylation
restores fibrotic lung fibroblast COX-2 expression
To examine whether COX-2 transcription is regulated epigen-
etically, cells were treated with the DNMT inhibitor, 5AZA or
HDAC inhibitor, TSA. Treatment of representative control and
fibrotic cell lines with 5AZA (0–10 μM), demonstrated a distinct
difference in response. Demethylation did not affect COX-2 ex-
pression in control fibroblasts (Figure 2A). In contrast, treatment
577c© 2016 The Author(s) This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0
I.C. Evans and others
Figure 1 Basal and TGF-β-induced levels of COX-2 mRNA in control
and fibrotic lung fibroblasts
Fibroblasts were grown to confluence, serum deprived for 24 h, and then
incubated for 3 h in medium alone (A) or in TGF-β1 at a concentration of
1 ng/ml (B), before RNA was extracted for quantitative real-time PCR.
Data are enumerated as mRNA levels relative to mean basal levels
in control cell lines. Each bar represents the mean +− S.E.M. for four
control, seven IPF and four SSc donor cell isolates. (***P< 0.001
compared with control, one-way ANOVA with Tukey’s post-test).
with 5AZA resulted in a dose-dependent increase in COX-2 ex-
pression in fibrotic lung fibroblasts, with levels higher at both 1
and 10 μM 5AZA compared with untreated cells (P< 0.01, in
both cases), and were similar to control. These data were con-
firmed by treatment of selected IPF and SSc fibroblasts with an
alternative DNMT inhibitor, Zebularine, which also increased
COX-2 mRNA approximately six-fold (Supplementary Figure
S2). Cells treated with 5AZA and TGF-β1 showed a similar pat-
tern of response (Figure 2B). Relative levels of TGF-β1-induced
COX-2 mRNA were three-fold lower in fibrotic lung fibroblasts
compared with the control cell line, in the absence of 5AZA.
Fibrotic fibroblast COX-2 mRNA levels increased in a dose-
dependent manner in response to 5AZA (P< 0.05) with expres-
sion increased greater than two-fold at 10 μM (P< 0.01). At the
10 μMdose of 5AZA, levels of COX-2 mRNA in the fibrotic cell
line were similar to that seen in control fibroblasts. Similar dose-
dependent responses were seen in other IPF- and SSc-derived
cell lines (results not shown). Group data for control, IPF- and
SSc-derived lung fibroblasts treated with 10 μM 5AZA is shown
in Figure 2C. DNA demethylation increased COX-2 expression
in control cell lines by two-fold (P< 0.05). In contrast, both IPF
and SSc fibroblast lines showed significantly greater increases
(four-fold) in COX-2 expression in response to 5AZA compared
with controls. Similar results were observed following stimula-
tion with TGF-β1 although the differences between control and
fibrotic groups were less marked (Figure 2D).
Previous studies have suggested that histone hypoacetylation
contributes to the dysregulation of COX-2 expression in IPF
lung fibroblasts [32]. Using TSA, we observed a trend towards
increased COX-2 mRNA expression compared with untreated
cells, in control and fibrotic fibroblasts, but this was not signific-
ant (Supplementary Figure S3A). Similar results were observed
following TGF-β1 treatment, with no significant difference ob-
served between the fibrotic and control groups (Supplementary
Figure S3B).
DNA demethylation restores fibrotic lung fibroblast
function
To investigate whether the up-regulation ofCOX-2mRNA seen in
fibrotic lung fibroblasts following treatment of cells with 5AZA
had functional downstream consequences, we measured the level
of PGE2, in cell supernatants (Figure 3A). Similar to the effects of
5AZA on COX-2 mRNA, two-way ANOVA demonstrated a stat-
istically significant difference in PGE2 production between con-
trol and fibrotic lung fibroblasts (P< 0.05) and a dose-dependent
response to demethylation was also observed in fibrotic fibroblast
PGE2 production (P< 0.005). Group data shows that basal levels
of PGE2 produced by control cells are significantly higher than
levels produced by both the fibrotic groups (P< 0.01, compared
with IPF and P< 0.05, compared with SSc) (Figure 3B). Treat-
ment of cells with 5AZA resulted in approximately three- and
two-fold increases in PGE2 production in IPF- and SSc-derived
fibroblasts respectively (P< 0.001 and P< 0.02 respectively).
PGE2 production by control cell lines was not altered by treat-
ment with 5AZA. Mean levels of PGE2 produced by both the
fibrotic groups following treatment with 5AZA were not signi-
ficantly different from those produced by controls.
Quantitative real-time PCR was used to analyse levels of col-
lagen mRNA production in both control and fibrotic lung fibro-
blasts. Basal levels of collagen 1A mRNA in IPF fibroblasts were
two-fold higher compared with control (Figure 3C). Treatment
with 5AZA did not affect collagen 1A expression in control cells;
whereas a dose-dependent and significant decrease in collagen
1A mRNA levels was observed in IPF fibroblasts (P< 0.01). At
the higher doses of 5AZA, there was no significant difference
between the collagen 1A expression measured in control and
fibrotic cells.
In agreement with our previous data [25], we demonstrate that
fibrotic lung fibroblasts are resistant to FasL-induced apoptosis
when compared with control (Figure 3D). Growth of fibrotic cells
with 5AZA led to a greater than three-fold increase in the sens-
itivity of these cells to FasL-induced apoptosis, compared with
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Figure 2 DNMT inhibition preferentially increases COX-2 mRNA levels in fibrotic lung fibroblasts
Proliferating cultures of control and fibrotic lung fibroblast lines were incubated with indicated concentrations of 5AZA for
96 h. Fibroblasts were then treated with medium alone (A) or with TGF-β1 (1 ng/ml) for 3 h (B) before being harvested
for COX-2 quantitative real-time PCR. Data are enumerated as the fold increase, relative to mean mRNA levels basally
in control cells. Each bar represents the mean of duplicate samples +− S.E.M. for one representative control and fibrotic
cell line (**P< 0.01 compared with 0 μM 5AZA, two-way ANOVA with Bonferroni post-test). Proliferating cultures were
incubated with 10 μM of 5AZA for 96 h and then treated with medium alone (C) or with TGF-β1 (1 ng/ml) for 3 h (D) before
being harvested for COX-2 quantitative real-time PCR. Data are enumerated as the fold increase, relative to mean levels
in non-5AZA treated cells. Each bar represents mean +− S.E.M. for four control, seven IPF and four SSc donor cell isolates
(*P< 0.05, **P< 0.01, compared with control group, one-way ANOVA with Tukey’s post-test).
non-AZA treated cells (P< 0.001), resulting in levels comparable
to that seen in control cells.
The COX-2 promoter is not differentially methylated
in fibrotic lung fibroblasts
In order to examine whether the effects observed in fibrotic
lung fibroblasts in response to 5AZA treatment, are a con-
sequence of a direct effect on COX-2, we used pyrosequen-
cing to investigate the methylation status of CpG sites within
the COX-2 promoter. Twenty-seven CpG sites were analysed
in three different regions (Supplementary Figure S4A), two of
which were previously identified as being methylation sensit-
ive and having a functional role in regulating COX-2 expres-
sion [33,34]. However, our data demonstrate that none of the
CpG sites/regions were hypermethylated in control or fibrotic
lung fibroblasts (Supplementary Figure S4B). Levels of methyl-
ation in both 5AZA and TGF-β1 treated cells were also analysed
and demonstrated no significant differences (results not shown).
These results were further confirmed by methylation microarray
analysis (Supplementary Figure S4C). Seventeen CpG sites were
analysed (five of which were previously assessed by pyrosequen-
cing) and no differential methylation was observed at any
position.
Identification of c8orf4 as a novel COX-2 regulator
in pulmonary fibrosis
The Illumina Infinium Human Methylation 450 array was used
to identify genes with altered methylation in IPF and SSc fibrotic
lung fibroblasts compared with control, and to identify genes
that may epigenetically regulate COX-2. The array contains
three probes corresponding to the promoter region of c8orf4
(Figure 4A). All three CpG sites were hypermethylated in all
IPF (n = 5) and SSc (n = 7) fibroblasts compared with con-
trol (n = 6); with on average a 24–40% higher methylation
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Figure 3 DNMT inhibition restores fibrotic lung fibroblast PGE2, collagen production and sensitivity to FasL-induced
apoptosis
Proliferating cultures of single representative control and fibrotic lung fibroblast isolates were treated with 0, 0.1, 1 or
10 μM 5AZA for 96 h. Cells were serum deprived for 24 h before cell supernatants were harvested for PGE2 enzyme
immunoassay. (A) Each bar represents the mean of duplicate samples +− S.E.M. (where no error bar is shown, only one
sample was available for analysis). Cells from each group (control; n = 4, IPF; n = 7, SSc; n = 4) were grown with
10 μM 5AZA before cell supernatants were collected for measuring PGE2 production (B). Each bar represents the mean+− S.E.M. (*P< 0.05, **P< 0.01, compared with control group, two-way ANOVA with Bonferroni post-test). Representative
control and fibrotic lung fibroblasts were incubated with 5AZA before being harvested for collagen 1A qPCR (C). Data are
enumerated as the fold increase, relative to mean mRNA levels basally in control cells. Each bar represents the mean
+− S.E.M. for three independent experiments (**P< 0.01 compared with 0 μM 5AZA, two-way ANOVA with Bonferroni
post-test. #P< 0.01 compared with basal levels in control). Representative control and fibrotic lung fibroblasts were
grown in the presence of either 10 μM 5AZA or vehicle alone, in medium containing 10 % FBS for 72 h (D). Fibroblasts
were then serum starved overnight with or without 5AZA prior to being exposed to FasL (50 ng/ml) for 24 h. Apoptosis was
determined by Annexin V/PI staining with FACS analysis. Bars represent the mean +− S.E.M. for six experimental replicates
(***P< 0.001 compared with non-5AZA treated, two-way ANOVA with Bonferroni post-test).
level in fibrotics compared with control, across all three sites
(Figure 4B). Methylation at two of these CpG sites (CpG 2 and
3) was confirmed by bisulfite sequencing (Figure 4C). A further
three CpG sites (CpG iv, v and vi) situated between CpG 2 and
CpG3 were also analysed by bisulfite sequencing (grey circles,
Figure 4A). Methylation levels at all five sites sequenced, were
on average 40–70% higher in both SSc and IPF compared with
control (Figure 4C).
Treatment of fibrotic lung fibroblasts with 1 μM 5AZA resul-
ted in a significant decrease in methylation levels at all five CpG
sites analysed within the c8orf4 promoter (Figure 4D). Bisulfite
sequencing data from representative control and fibrotic cell lines
shows no significant change in methylation in control fibroblasts
after treatment with 5AZA, at any of the CpG sites. However, in
fibrotic fibroblasts, methylation decreased by up to 65%. Group
data shows a significantly greater decrease in mean DNAmethyl-
ation over all CpG sites in the fibrotics compared with controls
(Figure 4E). The mean DNA methylation in the controls was not
significantly different from that in non-5AZA treated cells. How-
ever, on average, an 18% decrease in mean DNA methylation
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Figure 4 Increased methylation and decreased expression of c8orf4 in fibrotic lung fibroblasts
A schematic representation of the upstream 5′ region of c8orf4 (A). Circles indicate the location of CpG sites. Black
circles represent the three CpG sites on the Illumina array, grey circles represent three additional sites tested by bisulfite
sequencing and white circles represent untested CpG sites within the region. Genomic DNA extracted from primary
fibroblasts was assessed and mean percentage methylation at each CpG site within each group is shown (B). Genomic
DNA extracted from control, IPF and SSc cell lines were bisulfite treated and subjected to bisufite sequencing (C). Five
CpG sites within the c8orf4 promoter were analysed. Mean percentage methylation at each CpG site within each of the
groups is shown (C). For (B, C, E and F) data are derived from six control, five IPF and seven SSc donor fibroblast isolates.
***P< 0.001, **P< 0.01 and *P< 0.05, compared with levels in control cells, one-way ANOVA with Tukey’s post-test.
DNA extracted from representative control and fibrotic fibroblasts treated with or without 1 μM 5AZA for 1 week was
subjected to bisufite sequencing, as above (D). Each point represents the % methylation at the five individual CpG sites
analysed in panel C (***P< 0.001 compared with non-5Aza treated, two-way ANOVA with Bonferroni post-test). Control,
IPF and SSc lung fibroblast lines were treated with 1 μM 5AZA as above, and DNA subjected to bisulfite sequencing (E).
Data are enumerated as mean % DNA methylation across all five CpG sites within each group (*P< 0.05, compared with
levels in control cells). RNA extracted from control and fibrotic cell lines was subjected to qPCR for c8orf4 mRNA (F).
Data are enumerated as mRNA levels relative to mean basal levels in control cells (+−S.E.M., **P< 0.01 and *P< 0.05,
one-way ANOVA with Tukey’s post-test). Representative photomicrographs of control (n = 3), IPF (n = 6) and SSc (n = 1)
lung showing immunohistochemical localization of c8orf4 stained brown/black (G). Arrows indicate nuclear c8orf4 staining
in control lung fibroblast-like cells but staining was weak or undetectable in fibrotic lung fibroblasts (scale bar represents
50 μm).
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Figure 5 c8orf4 associates with the COX-2 promoter and knockdown in control fibroblasts down-regulates expression
of COX-2 and PGE2 production
Control fibroblasts were transfected with either a non-targeting negative control or c8orf4 siRNA (10 nM) and RNA was
extracted for qPCR (A and B). Levels of c8orf4 (A) and COX-2 (B) mRNA are represented as a percentage relative to
non-transfected cells (Nil). Each bar represents mean +− S.E.M. for three independent experiments. (*P< 0.05 compared
with Nil, one-way ANOVA with Tukey’s post-test). Protein samples were collected from cells transfected as above, and
samples Western blotted for COX-2 (C). Relative COX-2 levels are expressed as a ratio of COX-2/β -actin and represented
relative to levels in non-transfected cells. Cells were transfected as above, and cell supernatants were harvested for PGE2
enzyme immunoassay (D). Each bar represents the mean of triplicate wells +− S.E.M. and is representative of three indi-
vidual experiments (*P< 0.05 compared with non-transfected control, one-way ANOVA with Tukey’s post-test). Chromatin
extracted from representative primary control fibroblasts was immunoprecipitated with a c8orf4 antibody followed by PCR
with a panel of COX-2 promoter primer sets (E). ChIP PCR products, corresponding to region −579 to −1271, were visu-
alized by agarose gel electrophoresis (IgG corresponds to isotype control; input is sonicated but non-immunoprecipitated
sample and ntc is no template control for the PCR).
was observed, compared with non-5AZA treated fibrotic lung
fibroblasts.
Quantitative real-time PCR was used to assess whether dif-
ferences in methylation levels had any effect on the expres-
sion of c8orf4. Our results demonstrated that both IPF and SSc
fibroblasts on average had 2.5- and 5.5-fold lower levels, re-
spectively, of c8orf4 mRNA compared with control fibroblasts
(Figure 4F). In keeping with this finding, immunohistochemical
staining for c8orf4 on paraffin-embedded sections of human lung
tissue, shows intense nuclear staining in the control fibroblasts
(Figure 4G), whereas staining for c8orf4 in fibroblasts of fibrotic
lung was undetectable.
To examine whether c8orf4 regulates COX-2 transcription,
control fibroblasts were transfected with c8orf4 siRNA. A 40%
knockdown of c8orf4 mRNA was achieved with the c8orf4
siRNA, compared with non-transfected cells (Figure 5A). Trans-
fection with a non-targeting negative control siRNA, had no sig-
nificant effect on levels of c8orf4mRNA (ANOVA). Knockdown
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of c8orf4 additionally resulted in a 50% knockdown of COX-
2 mRNA, compared with non-treated cells with no significant
effects on COX-2 mRNA levels using a non-targeting control
siRNA (Figure 5B). Furthermore, Western blotting siRNA trans-
fected cell lysates using a COX-2 antibody, demonstrated an al-
most complete (95%) knockdown of the COX-2 protein in cells
transfected with c8orf4 siRNA (Figure 5C). Analogous to the ef-
fect seen on COX-2, transfection of cells with c8orf4 siRNA fur-
ther resulted in a 35% decrease in PGE2 production, compared
with non-treated cells (Figure 5D), whereas transfection with
non-targeting control siRNA had no effect. In order to determ-
ine whether c8orf4 is able to transcriptionally regulate COX-2,
we used chromatin immunoprecipitation to assess whether it was
able to bind to the COX-2 promoter. A panel of COX-2 promoter
primer sets spanning region +54 to −3654 was used to amplify
COX-2 DNA bound by the c8orf4 antibody (results not shown).
ChIP revealed the binding of endogenous c8orf4 to the COX-2
promoter, at region −579 to −1271 (Figure 5E).
DISCUSSION
We and others have previously demonstrated that pulmonary
fibroblasts derived from the lungs of patients with IPF and SSc
express significantly lower steady-state levels of COX-2 RNA,
compared with controls, basally and in response to TGF-β1
[6,31,32]. In the present study, we confirm this using quant-
itative real-time PCR for mature COX-2 mRNA transcripts and
additionally demonstrate, bymeasuring the production of nascent
COX-2 transcripts and use of actinomycin D, that the deficiency
in COX-2 expression in fibrotic lung fibroblasts is at the level of
transcription and is not due to altered RNAprocessing or stability.
Epigenetic regulation and in particular DNA methylation is
known to play a critical role in the transcriptional silencing of
genes [35]. Its role in tumorigenesis is well recognized, and there
is increasing recognition of a role in other disease settings, in-
cluding pulmonary fibrosis. It has been demonstrated that hyper-
methylation corresponds to the reduced expression of numerous
genes in IPF and SSc fibroblasts [16,17,36–38]. These include
the PTGER2 gene, which encodes the E prostanoid 2 receptor
(EP2), which is known to be a major receptor responsible for
anti-fibrotic effects of PGE2 [37,39]. We demonstrate that the
treatment of IPF and SSc fibroblasts, but not control fibroblasts,
with 5AZA resulted in a concentration-dependent increase in
COX-2 expression, PGE2 production, decreased collagen expres-
sion, as well as restoring sensitivity to apoptosis in fibrotic lung
fibroblasts. Together, these data indicate that DNA hypermethyl-
ation of COX-2/PGE2 pathway components may play a crucial
role in the dysregulated synthesis of this critical anti-fibrotic me-
diator, and contribute to pathogenesis of pulmonary fibrosis.
Hypermethylation of theCOX-2 promoter has previously been
shown to be responsible for gene silencing in cancer [21,33,34].
However, we found no evidence of CpG hypermethylation in the
COX-2 promoter or other gene regions tested, suggesting a dif-
ferent mechanism for COX-2 silencing in lung fibrosis to that
observed in cancer [33,34]. Consequently, this suggested an in-
direct epigenetic mechanism for down-regulation of COX-2 ex-
pression in fibrotic lung fibroblasts. One potential explanation
could be that a transcription factor or co-stimulatory molecule is
hypermethylated, preventing COX-2 transcription. Through mi-
croarray based screening of gene methylation, we discovered a
COX-2 regulatory factor, c8orf4, which is hypermethylated and
has reduced expression in both IPF and SSc lung fibroblasts.
This is consistent with previous data showing hypermethylation
of c8orf4 resulting in its reduced expression in cancer [40]. In ad-
dition, we demonstrate binding of c8orf4 to the proximal COX-2
promoter and that siRNA knockdown of c8orf4 in control fibro-
blasts reduced COX-2 expression and PGE2 synthesis analogous
with the phenotype of fibrotic lung fibroblasts.
C8orf4 encodes a small, highly conserved, nuclear localized
protein. Its structural characterization indicates that it performs
pivotal functions in the area of cell cycle control as well as tran-
scriptional and translational regulation [41,42]. c8orf4 has pre-
viously been linked to COX-2, where over-expression of c8orf4
in human aortic endothelial cells resulted in up-regulation of
COX-2 [43]. C8orf4, mainly studied in the context of cancer,
has more recently been linked to local inflammation and im-
mune responses [43–45]. In non-fibroblast cell types, it has been
demonstrated that c8orf4 can be up-regulated by TGFβ, IL-1β,
TNFα and LPS. These cytokines are known profibrotic mediators
that are also known to up-regulate PGE2/COX-2 in control lung
fibroblasts. Further, fibroblasts cultured from patients with IPF
fail to induce PGE2 synthesis on stimulation with these medi-
ators due to aberrant COX-2 expression [6,31,32,46]. Together
these data strongly suggest that hypermethylation and silencing
of c8orf4 inhibits the expression of COX-2 and PGE2, basally
and in response to profibrotic mediators, making an important
contribution to the pathogenesis of pulmonary fibrosis.
It is becoming apparent that multiple epigenetic mechanisms
are involved in the pathogenesis of fibrotic lung diseases. In ad-
dition to DNAmethylation, defects in epigenetic mechanisms in-
cluding histone modification, DNMT expression and miRNA ex-
pression have been implicated in the pathogenesis of pulmonary
fibrosis. Contrary to previously published data [32], we observed
a trend towards increased levels of COX-2 expression follow-
ing HDAC inhibition in control and fibrotic lung fibroblasts but
no clear differential between control or fibrotic lung fibroblasts,
basally or in combination with TGF-β1. Coward et al. [32] re-
port that combined HDAC inhibition and cytokine stimulation,
resulted in increased COX-2 expression in IPF lung fibroblasts.
However, only 2 out of the 11 fibrotic cell lines we tested demon-
strated an increased level of COX-2 expression in response to
HDAC inhibition and TGF-β1 stimulation. It would therefore ap-
pear that acetylation of histones may play a role in the regulation
of COX-2 but it is unclear whether there are differences between
control and fibrotic lung fibroblasts. Coward et al. also demon-
strated that total HDAC activity was reduced in IPF fibroblasts,
indicating that altered histone acetylation may play a wider role
in increasing the activity of other genes involved in IPF. More
recently, the same group have demonstrated that alterations in
histone methylation also play a role in regulating COX-2 expres-
sion [47]. A recent publication by Dakhlallah et al. [48] has added
another level of epigenetic regulation in IPF. They demonstrate
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that DNMT1 expression is regulated by several miRNAs. The
emerging data from this and other studies suggests that altered
epigenetic regulation is a complex but widespread and important
phenomenon in pulmonary fibrosis.
In summary, we have identified a COX-2 regulatory factor,
c8orf4, which is hypermethylated and down-regulated in fibrotic
lung fibroblasts and tissue compared with controls. These find-
ings add to the growing body of evidence which suggests that
aberrant DNA methylation is an important pathogenic feature
of pulmonary fibrosis. The reversibility of the epigenetic sup-
pression on COX-2 expression following DNMT inhibition, and
normalization of fibroblast function, implies that it may be pos-
sible to reprogramme the phenotype of fibrotic fibroblasts, and as
a result potentially improve the clinical outcome of patients with
pulmonary fibrosis. DNA demethylation agents are already li-
censed for clinical use. Our studies, together with others strongly
support the evaluation of epigenetically targeted therapies, pos-
sibly in combination with COX-2/PGE2 therapies for progressive
fibrotic lung disease. The evaluation of such novel therapeutic ap-
proaches is necessary for what is currently a progressive disease
with limited treatment options and a dismal prognosis.
CLINICAL PERSPECTIVES
• Reduced fibroblast expression of COX-2 and consequently
low levels of PGE2 are significant contributors to the fibropro-
liferation that characterizes pulmonary fibrosis. The mechan-
isms underlying this failure to up-regulate COX-2 are incom-
pletely understood.
• The present study demonstrates that the diminished capacity
of IPF and SSc lung fibroblasts to up-regulate COX-2 results
from aberrant epigenetic regulation. Hypermethylation and
silencing of c8orf4, a transcriptional regulator of COX-2 in
fibrotic lung fibroblasts, is a major contributor to their failure
to up-regulate COX-2. Consistent with this, knockdown of
c8orf4 in control fibroblasts induces a profibrotic phenotype.
• Targeting DNAmethylation may represent a novel therapeutic
approach for the treatment of pulmonary fibrosis.
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